Beijing, Mar. 29, 2018 — The China-U.S. Precision Medicine Summit, co-hosted by CEO Roundtable on Cancer, China Academy of Medical Sciences & Peking Union Medical College and sponsored by Thermo Fisher Scientific, took place on Thursday in Beijing, bringing together government, academic and industry leadership at the forefront of precision medicine in China and the U.S. The Summit was held to support accelerating the development of precision medicine to advance cancer treatments and improve human well-being.
As well as being a research focus in the U.S., breakthroughs in precision medicine are a primary focus of the Healthy China 2030 policy, issued by the State Council. The one-day summit, themed “Transforming Lives through Pioneering Precision Medicine” included keynote speakers such as Dr. Martin J. Murphy, Chief Executive Officer of CEO Roundtable on Cancer; Mr. Terry Branstad, U.S. Ambassador to China; Dr. Wang Chen, President of China Academy of Medical Sciences and Peking Union Medical College; Dr. Douglas Lowy, Deputy Director of U.S. National Cancer Institute (NCI); Prof. Zhan Qimin, President of Peking University Health Science Center (PKUHSC); Prof. Li Jin, President of Chinese Society for Clinical Oncology (CSCO); Dr. Wang Yu, Former Director General of Chinese Center for Disease Control and Prevention; Prof. Qiao Jie, President of Peking University Third Hospital; Prof. Liu Yuanli, Dean of School of Public Health, China Academy of Medical Sciences and Peking Union Medical College; Prof. Qin Jun, Director of National Center for Protein Science Beijing; Prof. Li Yixue, Director of Shanghai Center for Bioinformation Technology, who discussed crucial topics in precision medicine from the perspectives of policy, research and clinical applications, and called for action to increase collaboration between China and the U.S., as well as increasing collaboration across industries in China.
Panel discussion

Dr. WANG Chen, Summit Co-chair
President, China Academy of Medical Sciences & Peking Union Medical College
“Our collective goal is to deepen conversations and share insights to improve current cancer therapies and address unmet medical needs,” said Dr. Martin Murphy. “More importantly, the Summit serves as a great opportunity for us to learn from each other and foster collaboration in battling together to end cancer.”

“We actively support governments, academia, pharma/biotech and clinicians with technology and expertise to accelerate precision medicine research with a pathway to the clinic,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “The Summit enables the exchange of ideas that will lead to improved patient outcomes and lower cost of care.”
Mark Stevenson, Executive Vice President & Chief Operating Officer, Thermo Fisher Scientific

China-U.S. Precision Medicine Summit